Konica Minolta, Inc. & Innovation Network Corporation of Japan (INCJ) have closed a joint acquisition of Ambry Genetics Corporation—a pioneer & leader in genetic testing. Ambry is the first laboratory in the world to offer hereditary cancer panels and clinical exome sequencing.
According to Shoei Yamana, President and CEO of Konica Minolta, “This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine”.
Ambry & KM see the future of medicine as patient-focused. They partnered to accelerate the development of new diagnostic tests for many different diseases & more precise treatments for patients worldwide. Together—with their combined resources, technology & scale—they plan to advance biomedical research, globally.
According to Shoei Yamana, President and CEO of Konica Minolta, “This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine”.
Ambry & KM see the future of medicine as patient-focused. They partnered to accelerate the development of new diagnostic tests for many different diseases & more precise treatments for patients worldwide. Together—with their combined resources, technology & scale—they plan to advance biomedical research, globally.
